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Alzheimer’s disease (AD) is a late-onset, progressive degenerative disorder that affects mainly the judgment, emotional stability,
and memory domains. AD is the outcome of a complex interaction among several factors which are not fully understood yet;
nevertheless, it is clear that oxidative stress and inflammatory pathways are among these factors. 65 elderly subjects (42 cognitively
intact and 23 with probable Alzheimer’s disease) were selected for this study. We evaluated erythrocyte activities of superoxide
dismutase, catalase, and glutathione peroxidase as well as plasma levels of total glutathione, 𝛼-tocopherol, 𝛽-carotene, lycopene,
and coenzyme Q10. These antioxidant parameters were confronted with plasmatic levels of protein and lipid oxidation products.
Additionally, we measured basal expression of monocyte HLA-DR and CD-11b, as well as monocyte production of cytokines IL1-𝛼,
IL-6, and TNF-𝛼. AD patients presented lower plasmatic levels of 𝛼-tocopherol when compared to control ones and also higher
basal monocyte HLA-DR expression associated with higher IL-1𝛼 production when stimulated by LPS. These findings support the
inflammatory theory of AD and point out that this disease is associated with a higher basal activation of circulating monocytes that
may be a result of 𝛼-tocopherol stock depletion.
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
resulting in progressive neuronal death and memory loss
[1]. Histopathologically, the disease is characterized by intra-
neuronal neurofibrillary tangles (NFT) (aggregations of a
hyperphosphorylated form of the microtubule-associated
protein tau) and extracellular deposits of neuritic plaques
composed of amyloid-𝛽 (A𝛽) protein, a 40–43 amino acid
proteolytic fragment derived from the amyloid precursor
protein [2].
Although AD is considered a neurodegenerative disease,
both inflammation and oxidative stress are present early
and throughout its pathogenesis. One of the early clues as
to AD as an inflammatory process was the finding that
rheumatoid arthritis patients taking high levels of anti-
inflammatory drugs had a low incidence of AD [3]. Inflam-
matory mechanisms may significantly contribute to disease
progression and chronicity, with proinflammatory cytokines
(notably IL-1𝛼 and IL-1𝛽) being found throughout the brain
of individuals with AD when analyzed at autopsy [1]. Many
neuroinflammatorymediators including complement activa-
tors and inhibitors, chemokines, cytokines, reactive species,
and inflammatory enzymes are generated and released by
microglia, astrocytes, and neurons [4].
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However, the precise implications of the inflammatory
response for neurodegeneration have not been elucidated.
A current hypothesis considers that an extracellular insult
to neurons could trigger the production of inflammatory
cytokines by astrocytes andmicroglia.The cytokines, namely,
IL-1𝛽, TNF-𝛼, and IL-6, could affect the normal behavior of
neuronal cells. Therefore, dysfunction at this core level may
lead to abnormalities such as neurofibrillary degeneration in
AD [5].
It is well characterized that there is oxidative stress in the
AD brain. Lower plasma antioxidant levels and alterations in
antioxidant enzyme activities were reported inmild cognitive
impairment (MCI) patients and patients at early AD stages,
suggesting an imbalance between reactive species production
and antioxidant defense systems in the plasma ofADpatients.
This was substantiated by an increase in DNA, lipid, and
protein oxidation products found in blood and cerebrospinal
fluid (CSF) obtained from AD patients in comparison with
controls [6].
At the same time microglial cells activation is prominent
during AD. Microglia are bone marrow-derived cells of the
monocyte lineages that, like peripheral tissue macrophages,
become phagocytic and produce reactive oxygen species [3].
However, the evaluation of microglia activity during the
development of AD in human patients is impossible due to
its localization, thus justifying demand for models that use
parameters of easy access and reflecting the state of activation
of microglia. However, the studies with monocytes could
contribute to the understanding of inflammatory compo-
nent in AD, establishing, at the same time, the possibility
of using a minimally invasive technique, such as blood
collection.
As exposed, AD has an important component that
involves inflammatory reactions associated with reactive
species release and lower antioxidant levels. Thus, this paper
aims at verifying blood oxidative markers and monocyte
inflammatory parameters in elderly subjects who present
with very mild cognitive impairment.
2. Methods
2.1. Subjects. Patients participating in this study were part
of the last wave of Epidoso Project receiving monitoring on
aging by a multidisciplinary team [7].
65 elderly subjects (mean age 82 years) were selected for
this study. All patients had their functional capacity and labo-
ratory profile evaluated.These seniors were initially subjected
to a clinical survey conducted by a geriatrician, consisting
of history taking, physical examination, and evaluation of
mental autonomy, through the degree of cognitive function.
Patients with a history of cardiovascular disease, cancer, or
chronic inflammatory diseases as well as individuals with
current inflammatory alterations, assessed by erythrocyte
sedimentation rate or plasma levels of C-reactive protein,
were not included in this study.
The study protocol was submitted to the Ethics Commit-
tee of UNIFESP and was approved under number 0859/03.
All patients or their guardians signed informed consent.
2.2. Assessment of Patients’ Cognitive Ability. Minimental
state examination was used for screening cognitive deficits
among patients [8]. The maximum score is 30 and scores
lower than 24 were considered indicative of some kind of
cognitive dysfunction.
Patients who scored less than 24 points in MMSE were
then tested with CDR (Clinical Dementia Rating) [9, 10].
Patients were considered cognitively intact (INT group;
𝑛 = 42) when CDR was <1, while others were included in
the group of patients with probable Alzheimer’s disease (AD
group; 𝑛 = 23) if CDR was ≥1.
2.3. Measurements of Erythrocytes Parameters. Blood sam-
ples from participants were obtained after 12 hours of
fasting. Part of whole blood was used for flow cytometry.
After plasma separation, erythrocytes were used to measure
total glutathione content (TGSH) [11] and the remaining
hemolysate to assess the activities of antioxidant enzymes
[7], Cu-Zn superoxide dismutase (SOD), catalase (CAT), and
glutathione peroxidase (GPx), all adjusted by hemoglobin
concentration.
2.4. Measurements of Plasma Parameters. Plasma samples
were stored at −80∘C for later determination of 𝛼-tocopherol,
𝛽-carotene, lycopene, coenzyme Q10, and vitamin C [7]. For
extraction, 20𝜇L plasma aliquots were mixed with 100𝜇L
extraction solvent (50% ethanol proanalysis (pa), 50% 1-
butanol pa, containing 5mg butylhydroxytoluene/mL, and
8 𝜇mol Tocol/L as an internal standard) to extract the
vitamins and to denature plasma proteins. The sample was
then mixed by vortex for 30 s and centrifuged at 21 000×g
for 10min at 4∘C. The supernatant was transferred to a
polypropylene vial. This method uses precolumn and reverse
phase C18 column and UV-VIS detector with deuterium
lamp, with a mobile phase consisting of 80% acetonitrile, 3%
methanol (100mM ammonium acetate, 0.1% triethylamine),
and 15% dioxan. The mobile phase is pumped through the
system by a flow of 1.5mL/min with maximum pressure
of 350Kgf and the minimum of 0. The wavelength was
established by the method for each parameter and run time
for it was 4 to 6 minutes.
Plasma was also used to determine the concentration of
thiobarbituric acid reactive substances (TBARS) [7] and level
of oxidized proteins, expressed as plasma carbonyls [12].
2.5. Monocyte Activation Parameters. In order to evaluate
basal activation of circulating monocytes, cell surface HLA-
DR and CD-11b levels were assessed by flow cytometry, as
described elsewhere [13]. Monocytes were identified bymon-
oclonal antibodies anti-CD14-pernidin chlorophyll protein
(PerCP); neutrophils were excluded with CD66b-fluorescein
isothiocyanate (FITC) labeling. Cell surface molecules were
marked with anti-HLA-DR-phycoerythrin (PE) and anti-
CD11b-allophycocyanin (APC); controls were incubated with
anti-HLA-DR-PE and CD11b-APC isotypes.
Intracellular production of IL-1𝛼, IL-6, and TNF-𝛼
was quantified by flow cytometry in monocytes stimulated
with LPS and treated with monensin in order to prevent
Oxidative Medicine and Cellular Longevity 3
Table 1: Oxidative stress parameters in erythrocyte (RBC). Antiox-
idant enzymes: superoxide dismutase (SOD), catalase (CAT), and
glutathione peroxidase (GPx), and total glutathione level (TGSH).
INT (cognitively intact patients; 𝑛 = 42) and AD (patients with
probable Alzheimer’s disease; 𝑛 = 23). Values shown correspond
to the means ± SEM. Comparison between average results of
the groups was performed using Student’s 𝑡-test for independent
samples.
Parameter INT AD
RBC SOD (U/mg Hb) 7.82 ± 0.24 8.2 ± 0.31
RBC CAT (U/mg Hb) 187 ± 7 184 ± 8
RBC GPx (U/mg Hb) 12.8 ± 0.4 12.6 ± 0.7
RBC TGSH (mmol/Hb) 7.67 ± 0.21 7.45 ± 0.36
𝑃 < 0.05 was considered significant.
cytokine release [13]. Monocytes were identified by mon-
oclonal antibodies for surface staining (anti-CD66b-FITC
and anti-CD14-PerCP) and cytokine productionwas detected
using monoclonal antibodies anti-IL-1𝛼-PE, anti-IL-6-PE,
and anti-TNF𝛼-APC or their respective isotype controls.
Data were acquired using a FACSCalibur flow cytometer
and CellQuest software (both from BD Immunocytometry
Systems).
2.6. Reactive Oxygen Species Assay. Whole blood samples
were first stained with anti-CD14 PerCP for monocyte iden-
tification; samples were subsequently incubated with 2󸀠,7󸀠-
dichlorofluorescein diacetate (DCFH-DA), a stable com-
pound, nonfluorescent, which diffuses into the cells and
is hydrolyzed to 2󸀠,7󸀠-dichlorofluorescein (DCFH). Upon
cell stimulation with LPS, DCFH was oxidized to DCF by
reactive species, mostly H
2
O
2
, emitting high levels of green
fluorescence, which was detected by flow cytometry [14]
using a FACSCalibur flow cytometer and CellQuest software
(both from BD Immunocytometry Systems).
2.7. Statistical Analysis. Normality of data distribution was
assessed by Shapiro-Wilk test. Comparison between average
results of the groups was performed using Student t test for
independent samples. Correlation analysis between data was
performed using Spearman correlation test. All data were
processed and analyzed by appropriate statistical tests using
SPSS 17 software.
3. Results
No changes were observed on plasma activity of the major
erythrocyte antioxidant enzymes SOD, catalase, and glu-
tathione peroxidase (Table 1). Table 1 also shows that total
glutathione levels were similar in both cognitively intact
(INT) and in group of patients with probable AD.
Lipid peroxidation (measured as TBARS) and plasmatic
protein oxidation measured as the amount of circulating
protein carbonyls did not significantly differ between the
groups INT and AD (Table 2).
Plasma vitamin C levels were equivalent in both groups,
as illustrated in Table 2. Values of circulating 𝛼-tocopherol
Table 2: Oxidative stress parameters in plasma. INT (cognitively
intact patients; 𝑛 = 42) and AD (patients with probable Alzheimer’s
disease; 𝑛 = 23). Values shown correspond to the means ± SEM.
Comparison between average results of the groups was performed
using Student’s 𝑡-test for independent samples.
Parameter INT AD
Vitamin C (𝜇M) 48 ± 3 52 ± 5
𝛼-Tocopherol (𝜇M) 21 ± 1 17 ± 1∗
𝛽-Carotene (𝜇M) 0.79 ± 0.9 0.76 ± 1
Lycopene (𝜇M) 0.73 ± 0.09 0.67 ± 0.13
Coenzyme Q10 (𝜇M) 0.15 ± 0.02 0.13 ± 0.03
TBARS (thiobarbituric acid reactive
substances) (nmol/mL) 5.82 ± 0.51 5.83 ± 0.62
Oxidized proteins (nmol/mg prot) 0.14 ± 0.01 0.16 ± 0.02
∗
𝑃 < 0.05 was considered significant.
were about 20% lower in patients with probable Alzheimer’s
disease compared with cognitively intact patients. This dif-
ference was statistically significant. It was observed that the
two groups studied had similar plasma levels of 𝛽-carotene,
lycopene, and coenzyme Q10 (Table 2).
Table 3 shows that Cu, Zn-SOD activity had a positive
correlation with catalase and glutathione peroxidase activi-
ties, as well as total glutathione content. Catalase activity, in
turn, also had positive correlation with glutathione peroxi-
dase activity and total glutathione content in erythrocytes.
Glutathione peroxidase activity and total glutathione content
in red blood cells also had a significant positive correlation.
The same two parameters negatively correlated with lipid
peroxidation products in plasma.
Monocytes of patients with probable Alzheimer’s dis-
ease expressed approximately 70% more HLA-DR than the
cognitively intact patients. On the other hand, there were
no differences on the expression of CD11b by monocytes
obtained from the two groups (Figure 1 and Table 4).
The proportion of cells producing IL-1𝛼 was approxi-
mately 25% higher in patients with probable diagnosis of
the disease as compared to those cognitively intact (Table 4).
In the case of IL-6 and TNF-𝛼, there were no statistically
significant differences in the proportion of cells that produced
those interleukins (Figure 2 and Table 4).
The oxidativemetabolism ofmonocytes studiedwith flow
cytometry techniques showed no differences between groups
(Table 4).
4. Discussion
The aim of this study was to investigate the interrelationship
between AD, blood parameters of oxidative stress, and
indicators of inflammatory activity in monocytes. It follows
the reasoning by which monocytes are circulating cells that
resemble the brain microglia andmay even be recruited from
blood to brain tissue [15] in AD. Microglia are considered
the main element for the localized inflammatory events that
accompany this disease [16]. This would lead to localized
inflammation and increased production of reactive oxygen
4 Oxidative Medicine and Cellular Longevity
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Figure 1: Representative flow cytometric analysis of whole blood samples stainedwith anti-CD11b-APC (right column) and anti-HLA-DR-PE
(left column) monoclonal antibodies. From all events acquired in gate R1 (upper left graph), CD14-positive monocytes (gate R2, separated
from CD66b-positive neutrophils in gate R3; upper right graph) were used for histogram calculation of the geometric mean fluorescence
intensity (GMFI). A similar analysis was performed for the detection of fluorescent DCF in the ROS assay (histogram not shown). INT
(sample from cognitively intact patient) and AD (sample from patient with probable Alzheimer’s disease).
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Figure 2: Representative flow cytometric detection ofmonocyte intracellular production of IL-1𝛼, IL-6, and TNF-𝛼. Monocytes were selected
in a similar manner as described in Figure 1. LPS-induced production of each cytokine was determined by the percentage of events in the
upper right quadrant (%URQ). Only upper quadrants are shown. INT (sample from cognitively intact patient) and AD (sample from patient
with probable Alzheimer’s disease).
species, causing oxidative stress, which could be reflected by
circulating parameters [17].
In the conditions of this work, AD is not associated
with any evidence of systemic oxidative stress. Although
the activities of erythrocyte antioxidant enzymes do not
show changes in patients with AD, Spearman rank correla-
tion test reveals a positive correlation between the mutual
activities of erythrocyte superoxide dismutase, catalase, and
glutathione peroxidase and erythrocyte total glutathione
levels. These data confirm the validity of the postulate that
says that the body’s antioxidant systems act together in
an integrated manner. Spearman test has also identified a
negative correlation between the levels of lipid peroxidation
products, plasma glutathione peroxidase activity, and total
glutathione levels in erythrocytes. This fact indicates that
lipid peroxidation is influenced by the activity of antioxidant
glutathione peroxidase-glutathione system in this experi-
mental model. Indeed, glutathione-glutathione peroxidase
system is an important component of antioxidant protection
network to cells [18]. As a counterpoint to the measurement
of erythrocyte antioxidant activities, circulating levels of
oxidation products of macromolecules in the body have been
evaluated. To this end, we analyzed levels of plasma protein
carbonyls and plasma levels of lipid peroxidation products.
Plasma level of protein oxidation products is not altered in
AD compared with cognitively intact group. This lack of
change is found in some studies [18]. On the other hand,
some authors have found an increase of oxidized proteins
in plasma from AD patients [19, 20]. This difference may
be due to difference of sensitivity of the methods employed
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Table 3: Correlation between antioxidant erythrocytes parameters and plasmatic oxidation products. Superoxide dismutase (SOD), catalase
(CAT), glutathione peroxidase (GPx), total glutathione level (TGSH), and thiobarbituric acid reactive substances (TBARS). Analysis was
performed using the Spearman correlation test.
Spearman test SOD CAT GPX GSH TBARS
SOD
Coefficient of correlation 1.000 0.415∗ 0.316∗ 0.406∗∗ 0.097
Significance 0.001 0.011 0.001 0.244
CAT
Coefficient of correlation 0.415∗ 1.000 0.368∗∗ 0.317∗ 0.158
Significance 0.001 0.003 0.010 0.129
GPX
Coefficient of correlation 0.316∗ 0.368∗∗ 1.000 0.416∗∗ 0.323∗∗
Significance 0.011 0.003 0.001 0.009
TGSH
Coefficient of correlation 0.406∗∗ 0.317∗ 0.416∗∗ 1.000 0.253∗
Significance 0.001 0.010 0.001 0.034
TBARS
Coefficient of correlation 0.097 0.158 0.323∗∗ 0.253∗ 1.000
Significance 0.244 0.129 0.009 0.034
∗∗P < 0.01, ∗P < 0.05.
Table 4: Monocyte activation parameters. INT (cognitively intact
patients; 𝑛 = 42) and AD (patients with probable Alzheimer’s
disease; 𝑛 = 23); GMFI: geometric mean fluorescence intensity;
% URQ: percentage of events in the upper right quadrant. Values
shown correspond to the means ± SEM. Comparison between
average results of the groups was performed using Student 𝑡 test for
independent samples.
Parameter INT AD
HLADR (GMFI) 109.93 ± 10.59 177.74 ± 30.64∗
CD11B (GMFI) 406.74 ± 39.24 412.92 ± 48.97
IL-1𝛼 (%URQ) 65.78 ± 2.46 82.82 ± 6.52∗
IL-6 (%URQ) 52.89 ± 4.31 49.71 ± 6.57
TNF-𝛼 (%URQ) 6.85 ± 1.28 8.26 ± 2.47
Oxidative metabolism (GMFI) 266.32 ± 38.99 257.77 ± 63.07
∗
𝑃 < 0.05 was considered significant.
in the mentioned studies (two-dimensional electrophoresis,
mass spectrometry) in relation to enzyme-immunoassay
method chosen for this work and the possible differences in
quality of care and feeding among the target populations of
each study. Concentration of circulating lipid peroxidation
products is equivalent in both groups, results that agree with
those commonly found in the literature [18]. In general,
the population studied seems to enjoy a privileged status
in relation to nutritional populations examined in similar
studies in other locations. In addition to the antioxidant
profile outlined above, measurements of plasma levels of
nonenzymatic antioxidants of lowmolecularweightwere also
carried out.
Values of vitamin C, 𝛽-carotene, and 𝛼-tocopherol,
obtained in this study are within the range previously
described for a healthy population group in that age [7,
21]. A review of several published papers, performed by
Stocker and Frei [22], shows populational values for plasma
concentrations of vitamin C, 𝛼-tocopherol, and 𝛽-carotene
ranging from 30 to 150 𝜇M, 15 to 40 𝜇M, and 0.3 to 0.6 𝜇M,
respectively. Other authors report that, for cardiovascular
disease and cancer prevention, concentrations above 30𝜇M
𝛼-tocopherol in combination with concentrations greater
than 50 𝜇M of vitamin C, 0.4 𝜇M 𝛽-carotene, and 0.5𝜇M
lycopene are desired [23]. Thus, the two groups of elderly
patients studied have positioned themselves within the limits
found in several other studies to molecular plasma levels of
antioxidants.These parameters reflect part of the antioxidant
defense system of the body of patients, evaluating compo-
nents that can be absorbed directly from the diet, so further
promoted by the antioxidant defense mentioned above. Of
all lowmolecular weight antioxidants studied, only vitamin E
significantly differs between groups.The INT group has levels
of plasma vitamin E higher than those in AD patients.
This apparent homogeneity in antioxidant levels between
the various groups opposed to other studies in the literature
[24–27]. This finding, as previously mentioned, reinforces
the notion that the oxidative processes that are triggered
during the course of AD are not always reflected in circu-
lating blood, and even when that occurs, it may be only
an indication of other underlying mechanisms. Of special
interest is the fact that the establishment of AD, expressed
by the comparison between the INT and AD groups in
our study, is accompanied by the decrease of circulating
vitamin E, which possesses antioxidant capabilities as well
as recognized anti-inflammatory activities due to its action
on signal transduction mechanisms in phagocytes [28, 29].
Not surprisingly, studies that have obtained the best results in
preventing or treating AD in recent years used 𝛼-tocopherol
as an agent [30].
To complete the picture outlined up to this point, circulat-
ingmonocytes were analyzed by flow cytometry as indicators
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of inflammatory activity involved in AD. To this end, we
quantified the level of expression of surface molecules HLA-
DR, as an indicator of activation of circulating monocytes,
and CD-11b, an adhesion molecule involved in the process
of marginalization and migration of monocytes. The results
show that AD patients have circulating monocytes that
express higher amounts of HLA-DR on the surface even
without external stimulus, indicating a higher basal activation
state of these cells, confirming the data available in the
literature [31]. Markers of increased activation of monocytes
in the bloodstream are found in patients from a number of
neurodegenerative diseases [32]. As previously mentioned,
these circulatingmonocytes can cross the blood-brain barrier
andmigrate to the brain tissue, differentiating into microglia.
Since circulating monocytes of AD patients are more active
at baseline than those of INT, it can be postulated that
microglia derived from these cells react more intensely to
inflammatory stimuli, producing greater injury to brain.
Level of expression of surface protein CD-11b is the same in
both groups indicating that the potential for adhesion and
migration of these cells is not altered in this pathology.
Also by flow cytometry, monocytes production of IL-
1𝛼, IL-6, and TNF-𝛼 was measured. This measurement was
intended to evaluate the capacity of circulating monocytes
to stimulate the inflammatory process by attracting new
monocytes to the inflammatory site. The production of IL-1𝛼
is higher in monocytes from AD patients than in INT group.
Since IL-1𝛼 is an important proinflammatory cytokine, it is
plausible to assume thatmigration anddifferentiation of these
monocytes produce more active microglia. This increased
production of IL-1𝛼 was shown in vitro in human monocytes
lineage, when stimulated by P𝛽A, by means of mechanisms
of signal transduction mediated by tyrosine kinases, which
reinforces the above hypothesis [33].
Levels of IL-6 produced by stimulated peripheral mono-
cytes are similar in both groups, as well as of TNF-𝛼, agreeing
with Beloosesky et al. [34]. Other authors detected an
increase in IL-6 production bymonocytes of ADpatients [35]
using, however, a different stimulus (phytohemagglutinin)
than that used in this present study (LPS).
From the data shown here, it is reasonable to conclude
that AD is accompanied by the activation of circulating
monocytes and a decrease in circulating levels of vitamin E.
Several studies show 𝛼-tocopherol modulating inflammation
activity [28, 36]. In our study, the group of patients, where
plasma 𝛼-tocopherol is decreased, also showed more acti-
vated monocytes that respond to stimuli with an increased
production of proinflammatory cytokine IL-1𝛼. This study
points out that AD is associated with a higher basal activation
of circulating monocytes that may be a result of 𝛼-tocopherol
stock depletion.
Abbreviations
AD: Alzheimer’s disease
APC: Allophycocyanin
CDR: Clinical dementia rating
FITC: Fluorescein isothiocyanate
INT: Cognitively intact group
GMFI: Geometric mean fluorescence
intensity
LPS: Lipopolysaccharide
MMSE: Minimental state examination
PE: Phycoerythrin
PerCP: Periidinin chlorophyll protein
ROS: Reactive oxygen species
URQ: Upper right quadrant.
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